Vaneck Pharmaceutical ETF (PPH)

$90.00 +0.60 (0.67%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 106,427
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Phone: 888-658-8287
healthcareguru
healthcareguru Aug. 22 at 6:25 PM
$RCKT dramatic laggard in a ripping tape! Tells you the pump is GAME OVER. I warned you…it’s a bleeder now…enjoy that imminent >50% DILUTION, suckers!! 😂👎🐺 $XLV $IWM $PPH
0 · Reply
ZacksResearch
ZacksResearch Aug. 19 at 11:18 AM
$NVO just scored a historic FDA win ✅ Wegovy is now the first GLP-1 approved for MASH, sending shares up 5% and opening the door beyond obesity & diabetes. 📈 ETFs loaded with NVO like $OZEM, $THNR, and $PPH stand to gain. See the full ETF impact here 👉 https://www.zacks.com/stock/news/2734231/nvo-wins-fda-approval-for-mash-treatment-etfs-likely-to-gain?cid=sm-stocktwits-2-2734231-teaser-8260&ADID=SYND_STOCKTWITS_TWEET_2_2734231_TEASER_8260
1 · Reply
TalkMarkets
TalkMarkets Aug. 9 at 6:40 PM
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data $LLY $IHE $PPH $MEDX $OZEM https://talkmarkets.com/content/etfs/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?post=514413&userid=123969
0 · Reply
ZacksResearch
ZacksResearch Aug. 8 at 3:24 PM
$LLY drops hard after strong Q2 — is this the dip to buy? Solid earnings weren’t enough to offset weak obesity drug data, sending shares lower. But top-exposed ETFs like $IHE, $PPH, $MEDX and $MEDI could offer upside. Find out what makes these ETFs worth a closer look 👉 https://www.zacks.com/stock/news/2684363/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?cid=sm-stocktwits-2-2684363-teaser-6913&ADID=SYND_STOCKTWITS_TWEET_2_2684363_TEASER_6913
0 · Reply
ZacksResearch
ZacksResearch Aug. 8 at 2:21 PM
$LLY plunges 14% on disappointing weight-loss pill data despite crushing Q2 earnings! 📉 Eli Lilly beat both top and bottom line estimates, with a 61% EPS jump and a 38% revenue surge. Yet, disappointing weight-loss pill data overshadowed its strong performance and raised FY outlook. Is this a buying opportunity? Check the ETFs like $IHE, $PPH, $OZEM with big LLY exposure here 👉 https://www.zacks.com/stock/news/2684363/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?cid=sm-stocktwits-2-2684363-body-6878&ADID=SYND_STOCKTWITS_TWEET_2_2684363_BODY_6878
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 29 at 9:27 AM
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers $AZN $PPH $VTI https://stocktwits.com/news/equity/markets/astrazeneca-q2-beats-on-cancer-drug-sales-maintains-guidance-shares-rise-premarket/cho9ppoR5U0
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 21 at 4:19 PM
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided $MRK $PPH $PJP https://stocktwits.com/news/equity/markets/merck-blockbuster-drug-keytruda-gets-canadian-regulator-approval-for-treating-cervical-cancer/ch8AilFR5rS
0 · Reply
ZacksResearch
ZacksResearch Jul. 17 at 5:04 PM
$JNJ just lifted its 2025 outlook AND hiked its dividend 💥 A strong Q2 earnings beat is now fueling upside momentum in key healthcare ETFs like $IHE, $PPH, $XLV, and $IYH. See which ETF setups look strongest here 👉 https://www.zacks.com/stock/news/2588884/etfs-to-gain-on-jnjs-solid-q1-earnings-upbeat-outlook?cid=sm-stocktwits-2-2588884-teaser-2421&ADID=SYND_STOCKTWITS_TWEET_2_2588884_TEASER_2421
0 · Reply
ZacksResearch
ZacksResearch Jul. 17 at 2:06 PM
$JNJ rallies 6.1% post-earnings beat — should you jump in? 🚀 📈 EPS of $2.77 beats estimates, revenue up 5.8% from the prior year 🔄 Raised FY 2025 guidance & dividends, reduced expected tariff impact to $200 million from $400 million Discover ETFs like $IHE, $PPH, $XLV and $IYH to ride JNJ's growth wave 👉 https://www.zacks.com/stock/news/2588884/etfs-to-gain-on-jnjs-solid-q1-earnings-upbeat-outlook?cid=sm-stocktwits-2-2588884-body-2280&ADID=SYND_STOCKTWITS_TWEET_2_2588884_BODY_2280
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 11 at 3:37 PM
FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report $IHE $PPH $PJP https://stocktwits.com/news/equity/markets/fda-may-fast-track-new-drug-reviews-in-return-for-companies-lowering-drug-prices-report/ch8cizDR5ZU
0 · Reply
Latest News on PPH
PPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And Center

Jul 7, 2025, 8:23 PM EDT - 6 weeks ago

PPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And Center

Healthcare Sector Checkup As U.S. Looks To Change Regulations

May 30, 2025, 3:30 PM EDT - 3 months ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBC BBH BBP BIB BIS

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

May 8, 2025, 12:08 PM EDT - 3 months ago

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

IHE XPH

PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger

Apr 14, 2025, 9:15 AM EDT - 4 months ago

PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Feb 25, 2025, 11:06 AM EST - 6 months ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

IBB XLV AGNG ARKG BBC BBH BBP

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 7 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Final Trade: MSTR, PPH, TLT, MCD

Jan 7, 2025, 6:37 PM EST - 8 months ago

Final Trade: MSTR, PPH, TLT, MCD

MCD MSTR TLT

Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH

Oct 3, 2024, 12:13 PM EDT - 11 months ago

Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH

PPH: A Strong Fund To Play Big Pharma

Jul 18, 2024, 3:19 PM EDT - 1 year ago

PPH: A Strong Fund To Play Big Pharma

PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns

Apr 23, 2024, 4:34 AM EDT - 1 year ago

PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns

PPH: Ignore The Election Scare, Buy Pharma And Healthcare

Jan 19, 2024, 7:03 AM EST - 1 year ago

PPH: Ignore The Election Scare, Buy Pharma And Healthcare

Healthcare In 2024: Navigating The Biopharma Bull Run

Jan 17, 2024, 11:22 PM EST - 1 year ago

Healthcare In 2024: Navigating The Biopharma Bull Run

FHLC IBB IYH VHT XBI XLV

Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

Nov 16, 2023, 2:00 AM EST - 1 year ago

Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

BMY JNJ LLY PFE

Biotech Stocks Are Rallying, but the Outlook Isn't Good

Nov 15, 2023, 12:28 PM EST - 1 year ago

Biotech Stocks Are Rallying, but the Outlook Isn't Good

XBI XLV

PPH: A 'Shot In The Arm' For Investors Looking To Capitalize On Recent Pharmaceutical Advances

Oct 31, 2023, 3:35 AM EDT - 1 year ago

PPH: A 'Shot In The Arm' For Investors Looking To Capitalize On Recent Pharmaceutical Advances

PPH: GLP-1 Companies And Large-Cap Value Pharma Make For A Compelling Portfolio

Oct 29, 2023, 2:02 AM EDT - 1 year ago

PPH: GLP-1 Companies And Large-Cap Value Pharma Make For A Compelling Portfolio

PPH: Unnecessary Volatility In A Relatively Stable Healthcare Sector (Technical Analysis)

Jul 17, 2023, 2:46 PM EDT - 2 years ago

PPH: Unnecessary Volatility In A Relatively Stable Healthcare Sector (Technical Analysis)

How The Pharmaceutical Industry Is Using AI

May 14, 2023, 3:56 AM EDT - 2 years ago

How The Pharmaceutical Industry Is Using AI

AZN JNJ MSFT NVS

PPH Fell As Much As The Market Despite Resilience

Mar 24, 2023, 3:49 PM EDT - 2 years ago

PPH Fell As Much As The Market Despite Resilience

The Fall Of SVB: What It Means For Healthcare Startups

Mar 16, 2023, 3:51 PM EDT - 2 years ago

The Fall Of SVB: What It Means For Healthcare Startups

BBC BBH FBT IBB IHE IHF IHI

Betting On Biotech

Feb 10, 2023, 10:02 AM EST - 2 years ago

Betting On Biotech

DVA MRNA

PPH Might Be Too Safe For A Recovering Market

Jan 13, 2023, 5:28 PM EST - 2 years ago

PPH Might Be Too Safe For A Recovering Market

Can Health Care Stocks Outperform Again In 2023?

Jan 11, 2023, 6:09 PM EST - 2 years ago

Can Health Care Stocks Outperform Again In 2023?

AGNG ARKG BBC BBH BBP BMED CNCR

PPH Investors Should Keep On Top Of Regulatory Developments

Aug 26, 2022, 8:00 AM EDT - 3 years ago

PPH Investors Should Keep On Top Of Regulatory Developments

What The Inflation Reduction Act Means For Drug Prices

Aug 26, 2022, 1:24 AM EDT - 3 years ago

What The Inflation Reduction Act Means For Drug Prices

BBC BBH IBB IHE IHF IHI IYH

PPH: A Pharmaceutical ETF Delivering Close To 10% Total Return

Apr 13, 2022, 2:45 PM EDT - 3 years ago

PPH: A Pharmaceutical ETF Delivering Close To 10% Total Return

Pharma In Transition: Context And Opportunities

Mar 28, 2022, 2:32 PM EDT - 3 years ago

Pharma In Transition: Context And Opportunities

FTXH GSK JNJ PILL PJP SNY XPH

healthcareguru
healthcareguru Aug. 22 at 6:25 PM
$RCKT dramatic laggard in a ripping tape! Tells you the pump is GAME OVER. I warned you…it’s a bleeder now…enjoy that imminent >50% DILUTION, suckers!! 😂👎🐺 $XLV $IWM $PPH
0 · Reply
ZacksResearch
ZacksResearch Aug. 19 at 11:18 AM
$NVO just scored a historic FDA win ✅ Wegovy is now the first GLP-1 approved for MASH, sending shares up 5% and opening the door beyond obesity & diabetes. 📈 ETFs loaded with NVO like $OZEM, $THNR, and $PPH stand to gain. See the full ETF impact here 👉 https://www.zacks.com/stock/news/2734231/nvo-wins-fda-approval-for-mash-treatment-etfs-likely-to-gain?cid=sm-stocktwits-2-2734231-teaser-8260&ADID=SYND_STOCKTWITS_TWEET_2_2734231_TEASER_8260
1 · Reply
TalkMarkets
TalkMarkets Aug. 9 at 6:40 PM
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data $LLY $IHE $PPH $MEDX $OZEM https://talkmarkets.com/content/etfs/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?post=514413&userid=123969
0 · Reply
ZacksResearch
ZacksResearch Aug. 8 at 3:24 PM
$LLY drops hard after strong Q2 — is this the dip to buy? Solid earnings weren’t enough to offset weak obesity drug data, sending shares lower. But top-exposed ETFs like $IHE, $PPH, $MEDX and $MEDI could offer upside. Find out what makes these ETFs worth a closer look 👉 https://www.zacks.com/stock/news/2684363/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?cid=sm-stocktwits-2-2684363-teaser-6913&ADID=SYND_STOCKTWITS_TWEET_2_2684363_TEASER_6913
0 · Reply
ZacksResearch
ZacksResearch Aug. 8 at 2:21 PM
$LLY plunges 14% on disappointing weight-loss pill data despite crushing Q2 earnings! 📉 Eli Lilly beat both top and bottom line estimates, with a 61% EPS jump and a 38% revenue surge. Yet, disappointing weight-loss pill data overshadowed its strong performance and raised FY outlook. Is this a buying opportunity? Check the ETFs like $IHE, $PPH, $OZEM with big LLY exposure here 👉 https://www.zacks.com/stock/news/2684363/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?cid=sm-stocktwits-2-2684363-body-6878&ADID=SYND_STOCKTWITS_TWEET_2_2684363_BODY_6878
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 29 at 9:27 AM
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers $AZN $PPH $VTI https://stocktwits.com/news/equity/markets/astrazeneca-q2-beats-on-cancer-drug-sales-maintains-guidance-shares-rise-premarket/cho9ppoR5U0
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 21 at 4:19 PM
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided $MRK $PPH $PJP https://stocktwits.com/news/equity/markets/merck-blockbuster-drug-keytruda-gets-canadian-regulator-approval-for-treating-cervical-cancer/ch8AilFR5rS
0 · Reply
ZacksResearch
ZacksResearch Jul. 17 at 5:04 PM
$JNJ just lifted its 2025 outlook AND hiked its dividend 💥 A strong Q2 earnings beat is now fueling upside momentum in key healthcare ETFs like $IHE, $PPH, $XLV, and $IYH. See which ETF setups look strongest here 👉 https://www.zacks.com/stock/news/2588884/etfs-to-gain-on-jnjs-solid-q1-earnings-upbeat-outlook?cid=sm-stocktwits-2-2588884-teaser-2421&ADID=SYND_STOCKTWITS_TWEET_2_2588884_TEASER_2421
0 · Reply
ZacksResearch
ZacksResearch Jul. 17 at 2:06 PM
$JNJ rallies 6.1% post-earnings beat — should you jump in? 🚀 📈 EPS of $2.77 beats estimates, revenue up 5.8% from the prior year 🔄 Raised FY 2025 guidance & dividends, reduced expected tariff impact to $200 million from $400 million Discover ETFs like $IHE, $PPH, $XLV and $IYH to ride JNJ's growth wave 👉 https://www.zacks.com/stock/news/2588884/etfs-to-gain-on-jnjs-solid-q1-earnings-upbeat-outlook?cid=sm-stocktwits-2-2588884-body-2280&ADID=SYND_STOCKTWITS_TWEET_2_2588884_BODY_2280
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 11 at 3:37 PM
FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report $IHE $PPH $PJP https://stocktwits.com/news/equity/markets/fda-may-fast-track-new-drug-reviews-in-return-for-companies-lowering-drug-prices-report/ch8cizDR5ZU
0 · Reply
WallStCrush3r
WallStCrush3r Jul. 3 at 12:49 PM
$VRNA Wolfe Research initiated coverage of Verona Pharma with an Outperform rating and $170 $PPH
0 · Reply
sam92
sam92 Jun. 25 at 3:03 PM
$PPH SailPoint Named Overall Leader in 2025 KuppingerCole CIEM Leadership Compass Business Wire Tue, June 24, 2025 at 9:00 AM EDT https://finance.yahoo.com/news/sailpoint-named-overall-leader-2025-130000945.html
0 · Reply
sam92
sam92 Jun. 25 at 1:53 PM
$IMRX $IHE $PPH IMRX Immuneering Corp's Chief Scientific Officer Acquires Over 13,000 Shares Jun 24, 2025, 09:10 GMT-4
0 · Reply
sam92
sam92 Jun. 23 at 4:28 PM
$IMRX $IHE $PPH INSIDERS JUST KEEP BUYING Another INSIDER BUY IMRX SUPER BULLISH https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319255787&type=HTML&symbol=IMRX&cdn=7fe0c4bc942110040e6573a983589e90&companyName=Immuneering+Corporation&formType=4&formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&dateFiled=2025-06-23
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 17 at 5:23 PM
FDA Aims To Reduce Drug Application Review Time With New Voucher Program $IHE $PPH $PJP https://stocktwits.com/news/equity/markets/fda-aims-to-reduce-drug-application-review-time-with-new-voucher-program/chlp5PzRRce
0 · Reply
Sirtuan
Sirtuan May. 20 at 12:14 PM
$PPH $LLY $NVO $GILD big pharma looking pretty nice.
0 · Reply
sam92
sam92 May. 16 at 11:36 PM
$UNH $XPH $PPH Have a great weekend UNH millionaires ! Staying positive and looking good for a nice GAP up premarket Monday AM to over $305 to start the week . Should see reversal news blasts that have the proper tone of bullishness . Then we will all have the massive squeeze as it edges higher and higher through the week showing al what parabolic truly means . Feeling positive and grateful for the chance to obtain UNH shares as such a huge discount .
1 · Reply
PeterLynch_IsBack
PeterLynch_IsBack May. 16 at 3:09 PM
$PPH looks like a buy
0 · Reply
Sirtuan
Sirtuan May. 12 at 2:25 PM
$PPH $MRK $GILD nice move is pharma stocks today.
0 · Reply
Ro_Patel
Ro_Patel May. 11 at 11:34 PM
Pharma tariffs, price regulations, end PBM rebates, & expanding govt negotiations maybe in the cards $XLV $PPH $XPH $IBB $XBI
1 · Reply
TalkMarkets
TalkMarkets May. 8 at 7:41 PM
A Look At #Pharma #ETFs After Strong Q1 #Earnings $IHE $PJP $PPH $XPH $FTXH https://talkmarkets.com/content/etfs/a-look-at-pharma-etfs-after-strong-q1-earnings?post=496580
0 · Reply
ARMRreport
ARMRreport Apr. 14 at 4:46 PM
$PPH Trump signals imminent tariffs on U.S. pharmaceutical imports, according to Reuters
0 · Reply